Pinned
VitaDAO 💛
8,545 posts
VitaDAO 💛
@vitadao
VitaDAO is a community owned collective funding early stage longevity research,governed by $VITA-holders 🧬 👉discord.gg/vitadao
The VitaDAO May Longevity Newsletter is live. This month: - Cyclarity reports first Phase 1 data — UDP-003 drove dose-dependent 7KC excretion in humans - Repair Biotechnologies received FDA RDEP eligibility for REP-0003 in HoFH - The NAD debate continues, with a new paper and a- NewLimit is going after aging as a root driver by restoring cell function. Their prototype is now heading into the clinic next year. Good to see this approach moving forward. 🫡Aging is arguably the root cause of most major diseases (loss of function in our cells). Four years ago, we made a bet that aging was treatable, and NewLimit was born. NewLimit now has a prototype drug that reverses the age of some human cells (restores function they had when
- .@Cyclarity , backed by @vitadao, presented Phase 1 results for UDP-003 at AHA Vascular Discovery. First human evidence that 7-ketocholesterol (7KC), a driver of arterial plaque, can be safely excreted. All endpoints met, no SAEs. Phase 2 on plaque regression in 2026.
- VitaDAO 💛 reposted
Our flagship conference @DeSciBerlin is just one month away. Hosted in a brutalist church attached to an art gallery, it'll be our fifth year convening to discuss what the world looks like at the intersection of science and technology. Join us! - VitaDAO 💛 reposted
I'm looking forward to presenting @artan_bio's longevity pipeline and our decentralized model, which has helped us accelerate our work faster than traditional funding modalities. Longevity Day at @NFCsummit, Lisbon; June 4th, 2026. @vitarnabio @vitadao #Desci #longevity
- VitaDAO 💛 reposted
Atherosclerosis kills 20 million people a year. Statins slow plaque growth. Nothing approved today reverses it. Cyclarity just reported the first human evidence that oxidized cholesterol can be selectively removed from the body. Their drug, UDP-003, is an engineered - VitaDAO 💛 reposted
The first case of a SENS spinout getting this far! Massive congrats to Oki and his team. - Cyclarity Phase 1 of UDP-003 met all endpoints. First clinical evidence that humans can safely excrete 7-ketocholesterol, a root driver of atherosclerosis. Dose-dependent urinary excretion, no SAEs, ~3hr half-life. Phase 2 (plaque regression endpoint) planned later in 2026.
- VitaDAO 💛 repostedThanks @bradloncar for highlighting my work! I do think there’s interesting concepts in the DeSci space. Doing my part to shed light into it. @vitarnabio @vitadao @Molecule_sci @artan_bio𝐀𝐒𝐆𝐂𝐓 𝟐𝟎𝟐𝟔: @Mykalt45 isn't slowing down after selling his antibody-drug conjugate company to Eli Lilly. Here's his gene therapy play. Full video: biotechtv.com/post/asgct-202…
00:00 - VitaDAO 💛 repostedAnother VitaBeauty Update. In this experiment we were testing a few different sequences to rescue p53 in cells with an arginine nonsense mutation in p53, a well known tumor suppressor. You see a nice dose response between 5 ug and 10 ug. This is the Artan-102 (last lane) science
- VitaDAO 💛 repostedShows up translated to me, but awesome write up on what I’m bringing to the DeSci space. I work hard to create value for everyone around me and importantly, I make sure everyone wins as best I can. @vitarnabio @artan_bio $vitarna@BioProtocol + @vitadao 科学家 Michael Torres @Mykalt45 创立的 CrossBridge Bio，已被 Eli Lilly（礼来）以最高 3亿美元 收购，这笔交易让 Michael Torres 成为“从大学授权到被全球最大药企收购”的典型成功案例。 以下是BIO,VitaDao,CrossBridge Bio及Michael Torres之间的关系： 1.
